Growth Metrics

Madrigal Pharmaceuticals (MDGL) Change in Accured Expenses (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Change in Accured Expenses for 13 consecutive years, with -$88.4 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 1301.7% to -$88.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $131.9 million through Dec 2025, up 279.96% year-over-year, with the annual reading at $131.9 million for FY2025, 279.96% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$88.4 million at Madrigal Pharmaceuticals, down from $187.5 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $187.5 million in Q3 2025, with the low at -$88.4 million in Q4 2025.
  • Average Change in Accured Expenses over 5 years is $10.6 million, with a median of $2.8 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses surged 1712.96% in 2024, then tumbled 1301.7% in 2025.
  • Over 5 years, Change in Accured Expenses stood at -$3.5 million in 2021, then surged by 443.56% to $11.9 million in 2022, then crashed by 37.87% to $7.4 million in 2023, then plummeted by 185.59% to -$6.3 million in 2024, then crashed by 1301.7% to -$88.4 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$88.4 million, $187.5 million, and $33.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.